The CNIO develops an anti-obesity treatment in animal models

(Centro Nacional de Investigaciones Oncologicas (CNIO)) The study has been conducted on obese mice and monkeys, using a drug which inhibits the activity of the PI3K enzyme. The body weight loss was exclusively due to a reduction in fat mass and no toxic effects have been noted. The study also found an improvement in the symptoms of diabetes and hepatic steatosis (fatty liver disease). Obesity is one of the top risk factors within the spectrum of serious diseases that constitute metabolic syndrome.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news